Ask AI
H.R. 2130Became Law

Hillory J. Farias and Samantha Reid Date-Rape Drug Prohibition Act of 2000

Hillory J. Farias and Samantha Reid Date-Rape Drug Prohibition Act of 1999 - Directs the Attorney General to issue, within 60 days, a final order that schedules gamma hydroxybutyric acid (GHB) (together with its salts, isomers, and salts of isomers) in the schedule under the Controlled Substances Act (CSA) relating to imminent hazards to public safety, with specified exceptions regarding: (1) manufacture, distribution, or possession of the drug in accordance with an exemption under the Federal Food, Drug, and Cosmetic Act (FFDCA) involving drugs for research; and (2) new drug products under the FFDCA. Deems GHB to be so scheduled if such final order is not issued within that period.

Amends the CSA and the Controlled Substances Import and Export Act to provide additional penalties relating to GHB.

Adds gamma butyrolactone (GBL) as an additional list I chemical.

(Sec. 4) Amends the CSA to authorize the Attorney General to establish specified reporting requirements for GHB products in Schedule III, including annual reports of end-of-year inventories and requirements that dispensing practitioners maintain certain records regarding prescriptions.

(Sec. 5) Specifies that the designation of GBL or any other chemical as a listed chemical under the CSA does not preclude a finding that the chemical is a controlled substance analogue. Includes controlled substance analogues within the scope of provisions regarding penalties for distribution of a controlled substance.

(Sec. 6) Directs the Attorney General to: (1) develop model protocols for the collection of toxicology specimens and the taking of victim statements in connection with investigations into and prosecutions related to possible violations of the CSA or other Federal or State laws that result in or contribute to rape, other crimes of violence, or other crimes involving abuse of GHB, and other controlled substances, or so-called "designer drugs," and develop model training materials for law enforcement personnel involved in such investigations; and (2) make such protocols and training materials available to Federal, State, and local personnel responsible for such investigations.

Directs the Attorney General to make a grant, in such amount and to such public or private person or entity as the Attorney General considers appropriate, for the development of forensic field tests to assist law enforcement officials in detecting the presence of GHB and related substances. Authorizes appropriations. Sets forth reporting requirements.

(Sec. 7) Directs the Secretary of Health and Human Services to submit to Congress annual reports each of which provides an estimate of the number of incidents of the abuse of date-rape drugs that occurred during the most recent one-year period for which data are available, with the first such report submitted by January 15, 2000.

Requires the Secretary to develop a plan for carrying out a national campaign to educate young adults, youths, law enforcement personnel, educators, school nurses, counselors of rape victims, and hospital emergency room personnel on: (1) the dangers of date-rape drugs; (2) the applicability of the CSA to such drugs, including penalties; (3) recognizing the symptoms that indicate an individual may be a victim of such drugs, including symptoms of sexual assault; and (4) appropriately responding when an individual has such symptoms.

Directs the Secretary to: (1) establish an advisory committee, composed of individuals who collectively possess expertise on the effects of, and detecting and controlling, date-rape drugs, to make recommendations regarding the plan; and (2) commence carrying out the national campaign within 180 days after its establishment. Requires the Comptroller General to submit to Congress, within two years, an evaluation of the effects with respect to date-rape drugs of the national campaign.

(Sec. 8) Directs the Attorney General, within 60 days after this Act's enactment, to establish within the Operations Division of the Drug Enforcement Administration a special unit which shall assess the abuse and trafficking in GHB, flunitrazepam, ketamine, other controlled substances, and other designer drugs whose use has been associated with sexual assault, including: (1) examining the threat posed by such substances and drugs on a national and on a regional basis; and (2) making recommendations regarding allocations and reallocations of resources to address the threat.

Directs the Attorney General, within 180 days, to submit to specified congressional committees a report setting forth the recommendations of the special unit, and specifying the allocations and reallocations of resources that the Attorney General proposes to make in response to the recommendations.

Became Public Law No: 106-172.

Rep. Upton, Fred [R-MI-6](R-MI)Sponsor
21 cosponsors11 D10 R
21cosponsors2committees45actions4related bills70subjects
  1. PresidentE40000

    Became Public Law No: 106-172.

  2. BecameLaw36000

    Became Public Law No: 106-172.

  3. PresidentE30000

    Signed by President.

  4. BecameLaw36000

    Signed by President.

  5. FloorE20000

    Presented to President.

  6. President28000

    Presented to President.

  7. ResolvingDifferencesH41931

    Motion to reconsider laid on the table Agreed to without objection.

  8. ResolvingDifferencesH41610

    On motion that the House suspend the rules and agree to the Senate amendments Agreed to by the Yeas and Nays: (2/3 required): 339 - 2 (Roll no. 3). (consideration: CR H53-54; text: CR H55-57)

  9. NotUsed19500

    Resolving differences -- House actions: On motion that the House suspend the rules and agree to the Senate amendments Agreed to by the Yeas and Nays: (2/3 required): 339 - 2 (Roll no. 3).(consideration: CR H53-54; text: CR H55-57)

  10. ResolvingDifferencesH40142

    At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 5, rule I, the chair announced that further proceedings on the motion would be postponed.

  11. FloorH8D000

    DEBATE - The House proceeded with forty minutes of debate on the motion.

  12. ResolvingDifferencesH40140

    Mr. Upton moved that the House suspend the rules and agree to the Senate amendments.

  13. Floor

    Message on Senate action sent to the House.

  14. Floor

    Passed Senate in lieu of S. 1561 with an amendment and an amendment to the Title by Unanimous Consent.

  15. Floor17000

    Passed/agreed to in Senate: Passed Senate in lieu of S. 1561 with an amendment and an amendment to the Title by Unanimous Consent.

  16. Floor

    Senate struck all after the Enacting Clause and substituted the language of S. 1561 amended.

  17. Floor

    Measure laid before Senate by unanimous consent. (consideration: CR S14872-14877)

  18. IntroReferral

    Received in the Senate.

  19. FloorH38800

    The title of the measure was amended. Agreed to without objection.

  20. FloorH38310

    Motion to reconsider laid on the table Agreed to without objection.

  21. FloorH37300

    On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 423 - 1 (Roll no. 493). (text: CR H9863-9864)

  22. Floor8000

    Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 423 - 1 (Roll no. 493).(text: CR H9863-9864)

  23. FloorH30000

    Considered as unfinished business. (consideration: CR H9876-9877)

  24. FloorH37220

    At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.

  25. FloorH8D000

    DEBATE - The House proceeded with forty minutes of debate on H.R. 2130.

  26. FloorH30000

    Considered under suspension of the rules. (consideration: CR H9863-9872)

  27. FloorH30300

    Mr. Upton moved to suspend the rules and pass the bill, as amended.

  28. CalendarsH12410

    Placed on the Union Calendar, Calendar No. 214.

  29. DischargeH12300

    Committee on Judiciary discharged.

    Judiciary Committee
  30. Committee5500

    Committee on Judiciary discharged.

    Judiciary Committee
  31. IntroReferralH11210

    House Committee on Judiciary Granted an extension for further consideration ending not later than Oct. 8, 1999.

    Judiciary Committee
  32. CommitteeH12200

    Reported (Amended) by the Committee on Commerce. H. Rept. 106-340, Part I.

    Energy and Commerce Committee
  33. Committee5000

    Reported (Amended) by the Committee on Commerce. H. Rept. 106-340, Part I.

    Energy and Commerce Committee
  34. CommitteeH27200

    Ms. Pryce (OH) asked unanimous consent that the Committee on Commerce have until midnight on Sept. 7 to file a report on H.R. 2130. Agreed to without objection.

    Energy and Commerce Committee
  35. CommitteeH19000

    Ordered to be Reported (Amended) by Voice Vote.

    Energy and Commerce Committee
  36. CommitteeH15000-B

    Committee Consideration and Mark-up Session Held.

    Energy and Commerce Committee
  37. CommitteeH23000

    Forwarded by Subcommittee to Full Committee in the Nature of a Substitute by Voice Vote.

    Health and Environment Subcommittee
  38. CommitteeH22000

    Subcommittee Consideration and Mark-up Session Held.

    Health and Environment Subcommittee
  39. CommitteeH11000

    Referred to the Subcommittee on Health and Environment.

    Health and Environment Subcommittee
  40. CommitteeH11000

    Referred to the Subcommittee on Crime.

    Crime and Federal Government Surveillance Subcommittee
  41. IntroReferralH11100

    Referred to the Committee on Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Judiciary Committee
  42. IntroReferralH11100-A

    Referred to the Committee on Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  43. IntroReferralH11100

    Referred to the Committee on Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Energy and Commerce Committee
  44. IntroReferralIntro-H

    Introduced in House

  45. IntroReferral1000

    Introduced in House

Nov 19, 199935
Hillory J. Farias and Samantha Reid Date-Rape Drug Prohibition Act of 1999 - Directs the Attorney General to issue, within 60 days, a final order that schedules gamma hydroxybutyric acid (GHB) (together with its salts, isomers, and salts of isomers) in the schedule under the Controlled Substances Act (CSA) relating to imminent hazards to public safety, with specified exceptions regarding: (1) manufacture, distribution, or possession of the drug in accordance with an exemption under the Federal Food, Drug, and Cosmetic Act (FFDCA) involving drugs for research; and (2) new drug products under the FFDCA. Deems GHB to be so scheduled if such final order is not issued within that period.

Amends the CSA and the Controlled Substances Import and Export Act to provide additional penalties relating to GHB.

Adds gamma butyrolactone (GBL) as an additional list I chemical.

(Sec. 4) Amends the CSA to authorize the Attorney General to establish specified reporting requirements for GHB products in Schedule III, including annual reports of end-of-year inventories and requirements that dispensing practitioners maintain certain records regarding prescriptions.

(Sec. 5) Specifies that the designation of GBL or any other chemical as a listed chemical under the CSA does not preclude a finding that the chemical is a controlled substance analogue. Includes controlled substance analogues within the scope of provisions regarding penalties for distribution of a controlled substance.

(Sec. 6) Directs the Attorney General to: (1) develop model protocols for the collection of toxicology specimens and the taking of victim statements in connection with investigations into and prosecutions related to possible violations of the CSA or other Federal or State laws that result in or contribute to rape, other crimes of violence, or other crimes involving abuse of GHB, and other controlled substances, or so-called "designer drugs," and develop model training materials for law enforcement personnel involved in such investigations; and (2) make such protocols and training materials available to Federal, State, and local personnel responsible for such investigations.

Directs the Attorney General to make a grant, in such amount and to such public or private person or entity as the Attorney General considers appropriate, for the development of forensic field tests to assist law enforcement officials in detecting the presence of GHB and related substances. Authorizes appropriations. Sets forth reporting requirements.

(Sec. 7) Directs the Secretary of Health and Human Services to submit to Congress annual reports each of which provides an estimate of the number of incidents of the abuse of date-rape drugs that occurred during the most recent one-year period for which data are available, with the first such report submitted by January 15, 2000.

Requires the Secretary to develop a plan for carrying out a national campaign to educate young adults, youths, law enforcement personnel, educators, school nurses, counselors of rape victims, and hospital emergency room personnel on: (1) the dangers of date-rape drugs; (2) the applicability of the CSA to such drugs, including penalties; (3) recognizing the symptoms that indicate an individual may be a victim of such drugs, including symptoms of sexual assault; and (4) appropriately responding when an individual has such symptoms.

Directs the Secretary to: (1) establish an advisory committee, composed of individuals who collectively possess expertise on the effects of, and detecting and controlling, date-rape drugs, to make recommendations regarding the plan; and (2) commence carrying out the national campaign within 180 days after its establishment. Requires the Comptroller General to submit to Congress, within two years, an evaluation of the effects with respect to date-rape drugs of the national campaign.

(Sec. 8) Directs the Attorney General, within 60 days after this Act's enactment, to establish within the Operations Division of the Drug Enforcement Administration a special unit which shall assess the abuse and trafficking in GHB, flunitrazepam, ketamine, other controlled substances, and other designer drugs whose use has been associated with sexual assault, including: (1) examining the threat posed by such substances and drugs on a national and on a regional basis; and (2) making recommendations regarding allocations and reallocations of resources to address the threat.

Directs the Attorney General, within 180 days, to submit to specified congressional committees a report setting forth the recommendations of the special unit, and specifying the allocations and reallocations of resources that the Attorney General proposes to make in response to the recommendations.

Oct 12, 199936
Hillory J. Farias Date-Rape Prevention Drug Act of 1999 - Amends the Controlled Substances Act (CSA) to add gamma hydroxybutyric acid (GHB) to schedule I, ketamine to schedule III, and gamma butyrolactone (GBL) as an additional list I chemical.

Provides for a limited exemption from Schedule I manufacturing and distributing facility security requirements for facilities manufacturing and distributing GHB for a Food and Drug Administration (FDA)-approved clinical study, pursuant to the Federal Food, Drug, and Cosmetic Act, in which case Schedule III facility security requirements apply. Places an FDA-approved GHB drug product into Schedule III. Adds Schedule I penalties for the unlawful use of an approved drug product that contains GHB.

Specifies that the designation of GBL or any other chemical as a listed chemical under the CSA does not preclude a finding that the chemical is a controlled substance analogue. Includes controlled substance analogues within the scope of provision regarding penalties for distribution of a controlled substance.

(Sec. 4) Amends the CSA to authorize the Attorney General to establish specified reporting requirements for GHB products in Schedule III, including annual reports of end-of-year inventories and requirements that dispensing practitioners maintain certain records regarding prescriptions.

(Sec. 5) Directs the Attorney General to make a grant for the development of forensic field tests to assist law enforcement officials in detecting the presence of GHB and related substances.

(Sec. 6) Directs the Secretary of Health and Human Services to submit to Congress annual reports providing an estimate of the number of incidents of the abuse of date-rape drugs that occurred during the most recent one-year period for which data are available.

Requires the Secretary to develop a plan for carrying out a national campaign to educate young adults, youths, law enforcement personnel, educators, school nurses, counselors of rape victims, and hospital emergency room personnel on: (1) the dangers of the date-rape drugs; (2) the applicability of the CSA to such drugs, including penalties; (3) recognizing symptoms indicating that an individual may be a victim of such drugs, including symptoms of sexual assault; and (4) appropriately responding when an individual has such symptoms.

Directs the Secretary to establish an advisory committee to make recommendations to the Secretary regarding the plan.

Sets forth provisions regarding plan implementation and evaluation.

Sep 27, 199918
Hillory J. Farias Date-Rape Prevention Drug Act of 1999 - Amends the Controlled Substances Act (CSA) to add gamma hydroxybutyric acid (GHB) to schedule I, ketamine to schedule III, and gamma butyrolactone (GBL) as an additional list I chemical.

Provides for a limited exemption from Schedule I manufacturing and distributing facility security requirements for facilities manufacturing and distributing GHB for a Food and Drug Administration (FDA)-approved clinical study, pursuant to the Federal Food, Drug, and Cosmetic Act, in which case Schedule III facility security requirements apply. Places an FDA-approved GHB drug product into Schedule III. Adds Schedule I penalties for the unlawful use of an approved drug product that contains GHB.

Specifies that the designation of GBL or any other chemical as a listed chemical under the CSA does not preclude a finding that the chemical is a controlled substance analogue. Includes controlled substance analogues within the scope of provision regarding penalties for distribution of a controlled substance.

(Sec. 4) Amends the CSA to authorize the Attorney General to establish specified reporting requirements for GHB products in Schedule III, including annual reports of end-of-year inventories and requirements that dispensing practitioners maintain certain records regarding prescriptions.

(Sec. 5) Directs the Attorney General to make a grant for the development of forensic field tests to assist law enforcement officials in detecting the presence of GHB and related substances.

(Sec. 6) Directs the Secretary of Health and Human Services to submit to Congress annual reports providing an estimate of the number of incidents of the abuse of date-rape drugs that occurred during the most recent one-year period for which data are available.

Requires the Secretary to develop a plan for carrying out a national campaign to educate young adults, youths, law enforcement personnel, educators, school nurses, counselors of rape victims, and hospital emergency room personnel on: (1) the dangers of the date-rape drugs; (2) the applicability of the CSA to such drugs, including penalties; (3) recognizing symptoms indicating that an individual may be a victim of such drugs, including symptoms of sexual assault; and (4) appropriately responding when an individual has such symptoms.

Directs the Secretary to establish an advisory committee to make recommendations to the Secretary regarding the plan.

Sets forth provisions regarding plan implementation and evaluation.

Jun 10, 199900

Hillory J. Farias Date-Rape Prevention Drug Act of 1999 - Amends the Controlled Substances Act (CSA) to add gamma hydroxybutyric acid to schedule I, ketamine to schedule III, and gamma butyrolactone as an additional list I chemical.

Directs the Secretary of Health and Human Services to submit to Congress annual reports providing an estimate of the number of incidents of the abuse of date-rape drugs that occurred during the most recent one-year period for which data are available.

Requires the Secretary to develop a plan for carrying out a national campaign to educate young adults, youths, law enforcement personnel, educators, school nurses, counselors of rape victims, and hospital emergency room personnel on: (1) the dangers of the date-rape drugs; (2) the applicability of the CSA to such drugs, including penalties; (3) recognizing symptoms indicating that an individual may be a victim of such drugs, including symptoms of sexual assault; and (4) appropriately responding when an individual has such symptoms.

Directs the Secretary to establish an advisory committee to make recommendations to the Secretary regarding the plan.

Sets forth provisions regarding plan implementation and evaluation.